Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

Mark Zipkin
October 2, 2018 11:03 PM UTC

Discoveries that led to a pair of first-in-world approvals for two blockbuster cancer drugs from Bristol-Myers Squibb Co. (NYSE:BMY) and touched off a new era in treating cancer were the focus of this year's Nobel Prize for Medicine.

James Allison and Tasuku Honjo were jointly awarded the prize for their respective discoveries of cancer checkpoint targets CTLA-4 and PD-1...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bristol Myers Squibb Co.